氨磺必利与利培酮治疗首发精神分裂症对照研究

目的：比较氨磺必利与利培酮治疗首发精神分裂症患者疗效和安全性。方法：将96例符合中国精神障碍分类与诊断标准第3版精神分裂症诊断标准的患者随机分为两组，每组48例，分别给予氨磺必利与利培酮治疗8周，采用阳性与阴性量表（PANSS）及卡尔加精神分裂症抑郁量表（CDSS）评定疗效，治疗中出现的症状量表（TESS）评定不良反应。结果：治疗8周后氨磺必利组显效率70．8％，有效率87．5％，利培酮组显效率62．5％，有效率83．3％，两组疗效比较差异无统计学意义（P〉0．05），但两组PANSS阴性量表及CDSS减分比较，差异有统计学意义（P〈0．05），氨磺必利组高于利培酮组；两组不良反应发生率分别为氨磺必利组37．5％，利培酮组43．7％，两组差异无统计学意义（P〉0．05）。但对泌乳素及体重方面的影响，氨磺必利组影响更小。结论：氨磺必利与利培酮治疗精神分裂症总体疗效相似，但氮磺必利组能更好改善阴性症状及情感症状，不良反应少，且对体重及泌乳素影响更小。

Comparison the efficacy and safety of Amisulpride and Risperidone in treatment of schizophrenia patients with first episode

Objective ： To compare the efficacy and safety of Amisulpride and Risperidone in treatment of schizophrenia patients with first episode. Methods： Ninety - six schizophrenia patients with first episode who met the schizophrenia criterion of Chinese classi- fication of mental disorder （ CCMD - 3 ） were divided into two groups randomly and treated with Amisulpride or Risperidone for 8 weeks respectively. The positive and negative scale （PANSS）, Calgary Depression Scale for Schizophrenia （CDSS - C ） and treatment emer- gent side effect scale （TESS） were used to evaluate the efficacy and adverse effect respectively during the treatment. Results： The cure rate of Amisulpride group was 20.8% and efficacy rate was 87.5% after 8 weeks, which was 18.8% and 83.3% in Risperidone group. There were no statistical differences between these two groups （P 〉 0.05 ）. The incidence rate of adverse effect was 37.5% in Amisulpride group and that was 43.7% in Risperdone group. There were also no statistical differences between these two groups （P 〉 0.05 ）. However, in respect of prolactin and weight, Amisulpride group was less influence than Risperidone. Conclusions ： Amisul- pride and Risperdone appear to be similarly both in effective and adverse functions in the treatment of schizophrenia patients with first episode. We found Amisulpride may be somewhat more effective than Risperidone in treatment of affective and negative symptoms, in schizophrenia patients with first episode, and more tolerable in terms of weight and prolactin problems than Risperidone. These data, however, are based on only 8 weeks studies and therefore too limited to allow for firm conclusions.